Johnsen J, Mørland J
Incognito Klinikk, Oslo.
Acta Psychiatr Scand Suppl. 1992;369:27-30. doi: 10.1111/j.1600-0447.1992.tb03311.x.
Patient compliance with disulfiram is a troublesome clinical problem. Several strategies have been proposed as a solution to the problem, including subcutaneous implantation of disulfiram. However, well controlled studies of alcoholics and healthy volunteers have failed to discover a pharmacological effect of implanted disulfiram. A major reason for this failure appears to be poor absorption from an inadequate dose. Assessment of new sustained release formulation of depot disulfiram has been found to provoke a mild disulfiram-ethanol reaction (DER). Only a more severe DER would be expected to deter further drinking. If problems with absorption and appropriate dosing of disulfiram can be resolved or a depot preparation of the active metabolite of disulfiram can be prepared, implants might find continued clinical use.
患者对双硫仑的依从性是一个棘手的临床问题。已经提出了几种策略来解决这个问题,包括皮下植入双硫仑。然而,对酗酒者和健康志愿者进行的严格对照研究未能发现植入双硫仑的药理作用。这种失败的一个主要原因似乎是剂量不足导致吸收不良。已发现对长效双硫仑新剂型的评估会引发轻度双硫仑-乙醇反应(DER)。只有更严重的DER才有望阻止进一步饮酒。如果双硫仑的吸收和适当给药问题能够得到解决,或者能够制备双硫仑活性代谢物的长效制剂,植入物可能会继续在临床上使用。